Skip to content

Study · Non-randomized trial · n = 69 · 2018

4 results

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting.

Seaquist ER, Dulude H, Zhang XM, Rabasa-Lhoret R, Tsoukas GM, Conway JR, Weisnagel SJ, Gerety G, Woo VC, Zhang S, Carballo D, Pradhan S, Piché CA, Guzman CB

Diabetes, obesity & metabolism22 Mar 2018Cited by 40 (Europe PMC)

PMID29504662 (opens in a new tab)PMCIDPMC5947579 (opens in a new tab)DOI10.1111/dom.13278 (opens in a new tab)PepBankPUB-29504662
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with type 1 diabetes, hypoglycemic events resolved within 30 minutes of nasal glucagon in 95.7% of patients.

    In plain wordsIn adults with type 1 diabetes, hypoglycemic events resolved within 30 minutes after nasal glucagon in 95.7% of patients.

    Peptide
    Glucagon
    Outcome
    Not applicableHypoglycemic event resolution
    Study

    n = 69

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 mg · nasalAs given in this study (human).

    Measurements

    Patients with resolution
    95.7%
    within 30 minutes

    Source sentences

    Summary
    In 95.7% patients, HEs resolved within 30 minutes of NG administration.
    3 context sentences
    Summary · context
    In the efficacy analysis population, 69 patients experienced 157 HEs.
    Summary · context
    In the present multicentre, open-label, prospective, phase III study, we evaluated the real-world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate/severe hypoglycaemic events (HEs) in adults with type 1 diabetes (T1D).
    Summary · context
    Patients and caregivers were taught how to use NG (3 mg) to treat moderate/severe HEs, record the time taken to awaken or return to normal status, and measure blood glucose (BG) levels over time.
  2. 02HumanNon-randomized trialEfficacy outcome

    In adults with type 1 diabetes, all 12 severe events resolved within 15 minutes after nasal glucagon without additional external medical help.

    In plain wordsIn adults with type 1 diabetes, all 12 severe events resolved within 15 minutes after nasal glucagon without extra medical help.

    Peptide
    Glucagon
    Outcome
    Not applicableRecovery from severe hypoglycemia
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 mg · nasalAs given in this study (human).

    Measurements

    Severe events with recovery
    12 events
    within 15 minutes

    Source sentences

    Summary
    In all the 12 severe HEs, patients awakened or returned to normal status within 15 minutes of NG administration without additional external medical help.
    2 context sentences
    Summary · context
    In the present multicentre, open-label, prospective, phase III study, we evaluated the real-world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate/severe hypoglycaemic events (HEs) in adults with type 1 diabetes (T1D).
    Summary · context
    Patients and caregivers were taught how to use NG (3 mg) to treat moderate/severe HEs, record the time taken to awaken or return to normal status, and measure blood glucose (BG) levels over time.
  3. 03HumanNon-randomized trialOther

    Caregivers of adults with type 1 diabetes mostly reported that nasal glucagon was easy to use.

    In plain wordsMost caregivers of adults with type 1 diabetes reported that nasal glucagon was easy to use.

    Peptide
    Glucagon
    Outcome
    Not applicableEase of use
    Study

    n: not reported in source

    Outcome group
    Treatment Administration · Whole body
    Studied dose
    3 mg · nasalAs given in this study (human).

    Source sentences

    Summary
    Most caregivers reported that NG was easy to use.
    2 context sentences
    Summary · context
    In the present multicentre, open-label, prospective, phase III study, we evaluated the real-world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate/severe hypoglycaemic events (HEs) in adults with type 1 diabetes (T1D).
    Summary · context
    Patients and caregivers were taught how to use NG (3 mg) to treat moderate/severe HEs, record the time taken to awaken or return to normal status, and measure blood glucose (BG) levels over time.
  4. 04HumanNon-randomized trialSafety outcome

    In adults with type 1 diabetes treated with nasal glucagon, most adverse events were local and low to moderate in severity.

    In plain wordsIn adults with type 1 diabetes, most adverse events after nasal glucagon were local and low to moderate in severity.

    Peptide
    Glucagon
    Outcome
    Not applicableAdverse event location and severity
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    3 mg · nasalAs given in this study (human).

    Source sentences

    Summary
    Most adverse events were local and of low to moderate severity.
    2 context sentences
    Summary · context
    In the present multicentre, open-label, prospective, phase III study, we evaluated the real-world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate/severe hypoglycaemic events (HEs) in adults with type 1 diabetes (T1D).
    Summary · context
    Patients and caregivers were taught how to use NG (3 mg) to treat moderate/severe HEs, record the time taken to awaken or return to normal status, and measure blood glucose (BG) levels over time.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.